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ABSTRACT
Objectives Pruritus is a common and often distressing 
complication after a burn injury. The purpose of this 
review is to explore the efficacy of drugs classically used 
to treat neuropathic pain in the management of pruritus 
after burn injury.
Methods A systematic literature search of medical 
databases was conducted to find studies investigating 
drugs listed in the National Institute for Health and Care 
Excellence (NICE) guideline (CG173, “neuropathic pain in 
adults”) for the management of pruritus after burn injury 
in patients of any age. Controlled studies were stratified 
by the drug class studied and their risk of bias before 
conducting meta- analysis. A narrative review of case 
series or observational studies was presented. Severity 
of pruritus at any time point, with all quantitative and 
qualitative measures, was included.
Results Fifteen studies were included in the final 
analysis, 10 investigated the use of gabapentinoids, 
4 studied doxepin, and 1 local anesthetic agents. 
Meta- analysis of three randomized controlled trials 
(RCTs) demonstrated that the use of gabapentinoids 
was associated with an improvement in mean VAS 
(Visual Analog Scale) 0–10 scores of 2.96 (95% 
confidence interval (95% CI) 1.20 to 4.73, p<0.001) 
when compared with placebo or antihistamine. A 
meta- analysis of four RCTs investigating topical doxepin 
showed an improvement in mean VAS scores of 1.82 
(95% CI 0.55 to 3.09, p<0.001). However, when 
excluding two studies found to be at high risk of bias, 
no such improvement was found (−0.32, 95% CI −1.64 
to –0.99, p=0.83).
Conclusion This study suggests that gabapentinoids 
are beneficial in the management of burn- related 
pruritus. There is a lack of evidence to suggest that 
doxepin is an effective treatment. Topical local anesthetic 
agents may be safe and beneficial, but studies are scarce.
Level of evidence Systematic review, level II.
INTRODUCTION
Burn injuries are acute traumatic insults. However, 
even with successful treatment, it is increasingly 
recognized that such injuries have far reaching 
and long lasting consequences.1 After even rela-
tively minor burns, patients experience a persisting 
inflammatory response and immune dysfunction,2 
leading to an increased risk of cardiovascular 
disease,3 cancer,4 infections,5 and early death.6 
Although seemingly minor in comparison, pruritus 
is an additional long- term consequence that is 
common and significantly affects the quality of life 
of patients surviving burns.
There is a high prevalence of sensory disorders 
such as chronic pain, paresthesia, and pruritus 
in burns patients.7 The incidence of pruritus has 
been reported to be 93% at hospital discharge,8 
67% to 73% at 2 years,8 9 and 44% at 4 years to 
10 years.8 9 Factors such as deep dermal injury, 
greater total body surface area (TBSA) burned, an 
increased number of surgical interventions, female 
gender, and symptoms of post- traumatic stress 
disorder increase the risk.9
Achieving meaningful control of pruritus symp-
toms can be difficult and only a paucity of clinical 
trials have evaluated interventions.10–12 Histamine 
produced both from mast cell degranulation and 
as a by- product of collagen formation is thought 
to be a major contributor to the development of 
pruritus. A survey performed in the UK showed 
that over 90% of burns units used antihista-
mines as the first- line treatment.13 However, the 
involvement of various other peripherally acting 
pruritogens and the pathophysiological changes 
that occur more centrally mean that antihistamine 
monotherapy is often inadequate, especially in 
chronic pruritus.14
Although the neuronal pathways involved in the 
perception of pain have been extensively explored, 
the equivalent neuroanatomical basis for pruritus 
remains incompletely understood. A subset of 
afferent slow conducting C- fibers are activated 
by pruritogens including histamine, acetylcholine, 
calcitonin gene- related peptide, bradykinin, leukot-
rienes, prostaglandins, and various cytokines.15 Pain 
and pruritus share a similar neurophysiological 
basis, thought to be a consequence of evolutionary 
changes15 and after activation, these C- fibers 
conduct impulses in a similar manner to the pain 
pathway via the dorsal root ganglion, spinothalamic 
tract, thalamus, and then to various higher centers 
including the somatosensory cortex.14 15
Similarities have been drawn between chronic 
pruritus and neuropathic pain. Clinical features 
such as hyperknesis and alloknesis mirror the 
hyperalgesia and allodynia seen in neuropathic 
pain secondary to peripheral and central sensitiza-
tion.14 16 17 Such pathological processes are reflected 
in one classification of pruritus, as pruritogenic, 
neuropathic, neurogenic, and psychogenic.16
The objective of this narrative, systematic review 
is to evaluate the effectiveness of agents used in 
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Institute of Clinical Excellence (NICE),18 in the management of 
pruritus after a burn injury.
METHODS
Registration
This review was registered on the PROSPERO Register of 
Systematic Reviews, ID number CRD42020164777. The 
PRISMA (Preferred Reporting Items for Systematic Review and 
Meta- Analyses) guidelines for the conduct of systematic reviews 
were followed throughout.19
Eligibility criteria
Articles were included that investigated the management of 
pruritus in patients of any age that had sustained a burn injury 
with the use of neuropathic agents that are listed in the NICE 
guideline (CG173) “neuropathic pain in adults: pharmacological 
management in non- specialist settings”.18 Given the likelihood 
of several studies being observational in nature, no restrictions 
were made regarding the use of a control group. Animal studies, 
human volunteer studies, literature reviews, and conference 
abstracts were excluded, otherwise no restrictions on the type 
of study were made.
Search strategy
Three databases, MEDLINE, EMBASE and the Cochrane Central 
Register of Controlled Trials (CENTRAL), were searched with 
no time period or language restrictions (last accessed January 7, 
2021). The search strategies for each database can be found in 
the online supplemental material.
Study selection
After amalgamation of search results from the three sources and 
removal of duplicates, two authors (CM, WN) independently 
conducted a title review, abstract review, and then full article 
review to select articles for inclusion. Any disagreement between 
the two reviewers was resolved by a third reviewer (LP). The 
references of all titles included in the data analysis were screened 
for further articles to be included.
Data extraction
Data were extracted by CM using a predefined spreadsheet 
which included study design, patient demographics, interven-
tions, and outcomes. In the event of missing data, study investi-
gators were contacted.
Outcomes measured
The outcome of interest was the severity of pruritus at any time 
point. No specific restrictions were used, with all quantitative 
severity scales, qualitative measures, and questionnaire methods 
of assessment included. For inclusion in meta- analysis, any quan-
titative scales were converted to an 11- point continuous scale 
and the mean difference between groups reported.
Risk of bias assessment
Each included study was assessed independently by CM and 
WN using a specific risk of bias tool. The RoB2 (the updated 
Cochrane risk of bias tool) was used for randomized controlled 
trials (RCTs), and ROBINS- I tool for non- randomized studies. 
The quality of evidence for the outcomes of interest were assessed 
using the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluations) system.20
Data synthesis
Studies were categorized based on the intervention studied, 
specifically the neuropathic agent of interest, and are presented 
in tables for each class of agent. In controlled studies using the 
same drug or class of drug (eg, gabapentinoids) and comparable 
outcome measures (eg, a continuous variable such as visual 
analogue scale), results were collated using a random- effects 
meta- analysis, and two- sided p values and 95% confidence 
intervals were calculated. Heterogeneity was expressed as an I2 
statistic for studies included in meta- analyses. No specific sensi-
tivity analyses were performed; however, studies were stratified 
by their risk of bias and meta- analyses were conducted separately 
for those at high and low/moderate risk and then combined.
For agents where only case series or observational studies 
were available, a narrative review of the study findings was 
undertaken.









regimen Outcomes Follow- up
Zheng et al30 2015 Single center 
RCT
>5% TBSA, second 
degree burn, >80% 
healed or healed within 
3 months
58 18 to 60 1. Gabapentin
2. Cetirizine
3. Placebo
Gabapentin 300 mg twice 
daily
Pruritus VAS 28 days
Ahuja et al22 2013 Single center 
RCT
>5% TBSA, 80% 
epithelialized or healed 
within 1 month
80 18 to 60 Four groups:
1. Antihistamine




Pregabalin varied with 
severity of pruritus:
Mild—75 mg twice daily
Moderate—75 mg three 
times a day
Severe—150 mg twice daily
Pruritus VAS 28 days
Ahuja et al21 2011 Single center 
RCT
>5% TBSA, 80% 
epithelialized or healed 
within 1 month






Gabapentin varied with 
severity of pruritus:
Mild—300 mg once daily
Moderate— 300 mg twice 
daily
Severe—300 mg three times 
a day
Pruritus VAS 28 days
Gray et al24 2011 Single center 
RCT
Admitted to burn unit, 
>5% TBSA
90 18 to 65 1. Pregabalin
2. Placebo
Pregabalin 75 mg twice 
daily, titrated up to 150 mg 
twice daily or 300 mg twice 
daily based on clinical 
response
NPS (includes itch score 
0 to 10)
Procedural pain score 
0 to 10
4- point side effect scale
28 days
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Numeric data were extracted from graphs if the required data 
were not included elsewhere in an article using Graphgrabber 
(V.2.0.2, Quintessa Ltd, Oxfordshire, United Kingdom). Meta- 
analysis was conducted using the software package Revman 




The literature search returned 5469 articles after removal of 
duplicates. The PRISMA flowchart (see online supplemental 
figure S1) details the selection process. One article required 
translation from Chinese.
Three main classes of neuropathic agents were investigated in 
the articles included in the final analysis:
 ► Gabapentinoids (gabapentin and pregabalin).
 ► Topical doxepin.
 ► Topical local anesthetic agents.
Gabapentinoids
Ten articles21–30 investigated gabapentinoids in the management 
of pruritus after burn injury. Four studies were RCTs (table 1) 
and six were observational studies with varying methodology 
(table 2).
Randomized controlled trials
Three RCTs provided sufficient data to perform meta- analyses. 
Two studies21 30 included groups comparing gabapentin to a 
control arm given an antihistamine, cetirizine. Both studies 
demonstrated a mean reduction in pruritus severity, measured 
on 0 to 10 VAS (Visual Analog Scale) of around 6 points in the 
gabapentin group over the 28- day trial period. Those treated 
with cetirizine had a reduction of 3.9 and 3.5. The meta- analysis 
demonstrated a greater reduction in VAS score of 2.19 (95% 
CI 1.74 to 2.63) with gabapentin compared with cetirizine 
(figure 1).
Studies by Gray et al24 and Zheng et al30 included cohorts 
treated with a placebo. Gabapentinoids differed between studies, 
with Gray et al using pregabalin 150 o 600 mg daily and Zheng 
et al using gabapentin 600 mg daily. Meta- analysis demonstrated 
an improvement in 0 to 10 itch severity score of 3.63 (95% CI 
−1.20 to –8.46) when a gabapentinoid was used in comparison 
to placebo (figure 1).
Combination of the above subgroup meta- analyses demon-
strated an improvement in VAS of 2.96 (95% CI 1.20 to 4.73) 
when gabapentinoids are compared with control.
Although pruritus was not reported as a primary outcome 
in the study by Gray et al, it did report elements of the NPS 
(Neuropathic Pain Scale) including a 0 to 10 scale of pruritus 
Table 2 Observational studies of gabapentinoids




groups Dosing regimen Outcomes Follow- up
Kneib et al26 2019 Single center 
retrospective 
cohort study
Admitted to burn 
unit, complained 
of itch









Gabapentin 300 mg once 
daily increased every 
2 days if NRS≥5 to max 





Pain and itch NRS









In burn ward or 
outpatient clinic, 
complained of itch





Gabapentin 5 mg/kg Itch Man Scale 
0 to 4
Itch NRS (0 to 10)
1 week to 3 
months







136 0 to 20 Gabapentin only 
or in combination 
with pregabalin
Various gabapentin 
doses used from 50 mg 
three times a day to 
1200 mg three times a 
day. Pregabalin 50 mg 
to 100 mg three times a 
day added if inadequate 
response to gabapentin.
Retrospective 
review to describe 
effective dose of 
drugs
Unclear




Burn 6 weeks to 
2 years old, pruritus 
with failure of 
cetirizine and 
emollients
23 4 to 60 Gabapentin 
added if cetirizine 
inadequate
Adults—gabapentin 
100 mg twice daily, 
increased to max 300 mg 
three times a day
Children—5 mg/kg twice 
daily to max 5 mg/kg 
three times a day
Itch severity scale 
(7 to 21 points)
6 months




Within 72 hours of 
injury, admitted to 
burn unit, sense 
of itch and urge to 
scratch






or late, compared 
with pre- protocol 
data.
Adult 300 mg once daily 
titrated to 300 mg three 
times a day over 3 days
Children 5 mg/kg once 
daily titrated to 5 mg/kg 
three times a day over 
3 days









wound, admitted to 
burns unit
35 Children Gabapentin (no 
comparator or 
control)
5 mg/kg three times a 
day to max 5 mg/kg twice 
daily plus 10 mg/kg nocte
Staff or parent 
reporting of itch 
reduction
Unclear. Some 
followed up for 
18 months.
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severity. The effect of pregabalin on pruritus appeared much 
smaller than that demonstrated by the other studies included in 
the meta- analysis, with an improvement in mean scores of 1.17 
(95% CI 0.10 to 2.24).
A further RCT was not included in the meta- analysis.22 
Although the percentage changes in mean VAS scores were 
reported, the analysis did not include sufficient information 
regarding the distribution of the sample data, such as SD, to 
allow inclusion.22 This trial did, however, demonstrate a 78.9% 
fall in mean pruritus VAS scores in the group given pregabalin 
in comparison to 33.3% in the placebo group when focusing 
on patients with the most severe initial VAS scores (9 to 10). 
The placebo and antihistamine groups in this study suffered 
high dropout rates, however, potentially reflecting inadequate 
symptom relief.
Both RCTs conducted by Ahuja et al21 22 also included groups 
given a gabapentinoid and antihistamine in combination but found 
no additional benefit when compared with gabapentinoid alone.
Observational studies
Of the six observational studies (table 2), three were considered 
to be at serious risk of bias, two at moderate risk, and one to 
be of low risk (see online supplemental table S2). Sources of 
possible bias were primarily outcome measurements, which were 
often generated by research staff rather than patient reported.
Mendham et al27 reported improvements in itch intensity 
when gabapentin was used in children with persisting itch despite 
treatment with antihistamines. Unfortunately, this outcome was 
measured solely on subjective reporting by nursing staff, parents, 
and children.
Goutos et al23 investigated the use of two antipruritic proto-
cols, with early or late introduction of gabapentin as part of incre-
mental pharmacotherapy. In 41.5% of patients given gabapentin 
as the first- line agent, satisfactory itch control was achieved, in 
comparison to just 10% when cetirizine was used first line.
Zachariah et al29 reported improved mean itch severity scores 
when gabapentin was given to pediatric and adult patients 
complaining of pruritus with inadequate relief on antihistamines 
and emollients. On a scale ranging from 7 to 21, mean itch severity 
scores fell from 13.35 to 8.36 within 1 month of treatment and this 
effect was sustained for the 6- month follow- up period.
Kaul et al25 conducted a retrospective review of drug prescribing 
data of 136 mainly pediatric patients given gabapentin, prega-
balin, or a combination of both for pruritus or neuropathic 
pain. Although 91.4% of patients had an adequate response to 
treatment with gabapentin alone for pruritus, the measure of 
this outcome relied on adequate documentation in the patient 
medical notes and there was no comparator or control group.
Nieuwendijk et al28 investigated the incidence, severity, and 
risk factors associated with pruritus in pediatric burn injury, then 
went on to describe pharmacotherapies used with 17.9% having 
received gabapentin. Unfortunately, as the study was principally 
designed to explore factors associated with pruritus, no conclu-
sions could be drawn on the effectiveness of the pharmacological 
therapy.
Kneib et al26 conducted a retrospective cohort study inves-
tigating the use of a neuropathic pain and pruritus protocol. 
Patients were started on incremental doses of gabapentin if itch 
scores remained greater than 4 (on 0 to 10 NRS) despite initial 
treatment with cetirizine. Comparison was made between various 
groups including pre- protocol and post- protocol introduction 
as well as patients that received gabapentin early (<72 hours), 
late (>72 hours), or not at all. There was no difference in itch 
severity odds ratios between any group at discharge through to 
24 months.
Topical doxepin
Doxepin is a tricyclic antidepressant agent, but due to its potent 
antihistaminergic activity, is used topically to treat pruritus in 
eczema. Four studies31–34 investigated the use of topical doxepin 
on pruritic burn scars in adult patients (table 3). Given signifi-
cant differences in both the results of these studies and the risk of 
bias assessments, meta- analyses are presented on studies at high 
risk and low/moderate risk of bias separately and then combined 
(figure 2).
Demling et al performed two single center RCTs comparing 
topical doxepin to standard care.31 34 The results of both trials 
showed a marked improvement in itch VAS scores at all time 
points compared with standard care. The results of a meta- 
analysis including these studies demonstrated an improvement 
in mean VAS score of 3.10 (95% CI 2.73 to 3.47). Both of 
these studies were found to be at high risk of bias from a lack of 
blinding and unclear randomization methods (see online supple-
mental table S1). Additionally, the control arm of “standard 
care” involved titration of oral antihistamines that all partici-
pants were already taking prior to enrollment rather than intro-
duction of another therapy or placebo.
Kwa et al conducted two multicenter, blinded RCTs investi-
gating the use of doxepin cream. The first study32 showed no 
difference in itch intensity at any time point between doxepin 
Figure 1 Forest plot showing the reduction in mean VAS (Visual Analog Scale) in each treatment arm, comparing gabapentinoids with controls. 
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cream and the control group. Due to difficulty recruiting to the 
trial and a high dropout rate, this study was underpowered. A 
second study33 addressed these recruitment issues using a cross- 
over study design comparing doxepin against placebo without 
the inclusion of an antihistamine. Again, this demonstrated no 
difference in itch intensity between groups. A meta- analysis of 
both articles by Kwa et al (figure 2) using outcome data at 14 
days showed no difference in changes in VAS scores in compar-
ison to placebo or antihistamines, with a mean VAS change of 
−0.32 (95% CI −1.64 to 0.99).
All four studies investigating doxepin have been included in 
the final meta- analysis (figure 2) with no adjustment made for 
the risk of bias assessment. This demonstrated a reduction in 
mean VAS of 1.82 (95% CI 0.55 to 3.09). This result should 
be interpreted with caution as, when assessed using the GRADE 
tool, was found to be of very low quality, principally due to the 
high risk of bias (see online supplemental table S3).
Topical local anesthetics
One study35 investigated the use of a topical local anesthetic agent 
in the management of pruritus after burn injury in children 1 to 
5 years old. EMLA cream, a mixture of prilocaine and lidocaine, 
was applied to healed partial thickness burns with persisting 
pruritus in five patients. The main purpose of this study was to 
assess the safety and pharmacokinetics of this therapy.
This study was performed over 3 days, with the first 2 days 
acting as a control for the treatment being implemented on day 
3. There was an improvement in itch intensity as measured by a 
VAS and number of pruritic episodes. Owing to the young age of 
the children, outcome measures were made by parents, nursing 
staff, and the study investigators, potentially introducing an 
element of bias. This study suggested that the use of such topical 
local anesthetic agents was safe and may have potential benefit.
DISCUSSION
This systematic review identified 15 studies investigating the use 
of various drugs often used to manage neuropathic pain to treat 
pruritus after burn injury. The analysis has demonstrated that 
gabapentin is effective in treating pruritus after a burn injury, 
resulting in an improvement of around 2 points on a VAS when 
compared with antihistamines.
When compared with placebo, gabapentinoids were also bene-
ficial, although the confidence intervals in the meta- analysis were 
wide. The drugs used in each of the two included studies also 
differed, as did the indication for their initiation. Zheng et al30 
investigated gabapentin in the management of pruritus, whereas 
Gray et al24 investigated the use of pregabalin in patients with 
neuropathic pain, demonstrating a much smaller improvement 
in pruritic symptoms. This perhaps reflects the patient selection 
in this study whereby pain was the cardinal symptom, rather 
than pruritus. Given these limitations, it is therefore not possible 
to conclude whether this improvement is reproducible among 
the class of gabapentinoids or only evident with gabapentin.
Gabapentinoids are now used for a wide variety of indica-
tions. Although structurally similar to the inhibitory neurotrans-
mitter GABA (gamma aminobutyric acid) found throughout the 
Table 3 Studies of topical doxepin
Study Year Setting/design Inclusion criteria
Patient 
number Intervention Control Outcomes Follow- up
Kwa et al33 2020 Multicenter cross- 
over RCT
Healed burn, itch VAS≥3, 
pruritic area <10%
27 Doxepin cream Placebo cream Pruritus VAS
BIQ at week 2 and week 5
5 weeks
Kwa et al32 2019 Multicenter RCT Healed burn, itch VAS≥3 31 Doxepin cream 
and placebo tablet








Demling et al34 2003 Single center RCT Healed, <35% TBSA partial 
thickness burn, pruritic 
area <20%
31 Doxepin Standard care Pruritus VAS
Erythema (Vancouver Scar Scale)
12 weeks
Demling et al31 2002 Single center RCT Healed burn, pruritic 
area <15%
41 Doxepin Standard care Pruritus VAS
Erythema (Vancouver Scar Scale)
12 weeks
BIQ, Burn Itch Questionnaire; QOL SF- 36, Quality of Life Short Form- 36 questionnaire; VAS, Visual Analog Scale.
Figure 2 Forest plot showing the reduction in mean VAS (Visual Analog Scale) in each treatment arm, comparing topical doxepin with controls. 95% 
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central nervous system they do not act on GABA receptors and 
their benefit in the management of pain and pruritus is likely to 
be due to action at voltage- gated calcium channels and NMDA 
(N- methyl D- aspartate) receptors within the spinal cord and 
brain, inhibiting the release of excitatory neurotransmitters.36
Previous studies have demonstrated the benefit of gabapenti-
noids in reducing central sensitization and wind- up phenomenon 
to an acute painful stimulus in an effort to treat neuropathic 
pain.37 38 Such pathophysiological changes are characterized by 
alterations in the function of nociceptive neuronal pathways in 
response to persistent activation, inflammation, or injury. These 
changes lower the thresholds by which nociceptive neurons are 
activated, resulting in chronic pain syndromes and additional 
features such as hyperalgesia and allodynia.39 Given similar theo-
ries have been outlined to explain the pathological changes that 
result in chronic pruritus after burn injury, it is therefore logical 
that gabapentinoids may improve itch.14
The anti- neuropathic effects of gabapentinoids are increasingly 
used in a spectrum of pruritic and painful conditions, many of which 
these drugs are not licensed for.40–49 Such expanding uses of these 
drugs have seen an increase in gabapentinoid prescriptions across 
the UK, Europe, and North America.50–53 However, the potential 
harm from such agents, particularly gabapentinoids, is becoming 
clear. A systematic review of 59 studies highlighted the increasing 
use of gabapentinoids for recreational use and abuse.54 In Scotland, 
gabapentinoids are increasingly implicated in drug- related deaths, 
with toxicology reports from 2017 implicating gabapentin in 14% 
of such deaths and pregabalin in 12%.50 Given the risks of depen-
dence and harm with the use of these drugs,50 55–57 gabapentin and 
pregabalin were categorized as Class C controlled substances in the 
UK in April 2019.58 In the USA, pregabalin has been a Schedule 5 
controlled substance since its release in 2005 and some states have 
recently reclassified gabapentin in the same category. Patients with a 
previous history of psychiatric comorbidity, alcohol, or drug misuse 
are at even higher risk of harm when prescribed gabapentinoids.54 55 
In the context of individuals suffering a burn injury, such comor-
bidities are not uncommon, prompting vigilance when prescribing 
these drugs.59–61
Furthermore, more work is required to establish the clin-
ical significance of a reduction in VAS of around 2 points when 
compared with antihistamines alone, particularly given the poten-
tial for harm. The threshold whereby a treatment effect measured 
on such a scale is considered beneficial remains a topic of debate.62
Although observational data suggest topical EMLA may be a safe 
and potentially effective therapeutic option when used on healed 
burn wounds in children, such therapy will be limited by the size 
of pruritic area. Systemic absorption and the risk of local anesthetic 
toxicity must always be considered, particularly with larger areas of 
application. Topical lidocaine is increasingly being used in multiple 
conditions63–67 but the evidence for benefit in neuropathic pain is 
lacking, with NICE concluding that the evidence is insufficient to 
issue any recommendation on its use.18 Topical lidocaine, however, 
has been effective in managing pruritus in animal models,68 pruritus 
ani,69 and notalgia paresthetica.70
Although topical doxepin showed promise in healed burn 
wounds in early studies, such results have not been replicated 
in more recent trials described in this review. Although our 
meta- analysis of all studies investigating doxepin suggests an 
improvement in pruritic symptoms, this should be interpreted 
with caution due to the high risk of bias of two of the included 
studies.
This systematic review has several limitations. The paucity of 
RCTs included in our final analysis reflects the quality of evidence 
investigating these drugs in patients with burns. This resulted in 
only small numbers being included in the meta- analyses and a 
narrative review being conducted for the remaining studies.
Although the drugs we investigated are classically used to 
manage neuropathic pain, we elected not to focus on this specific 
pain condition, but rather pruritus given the increasing use of 
such drugs in other pruritic disorders and the recognized clin-
ical and pathophysiological similarities between neuropathic 
pain and pruritus. Although some studies have demonstrated a 
reduction in morphine consumption and improved acute pain 
scores with the use of gabapentin,71–73 there is a lack of evidence 
studying their specific use in neuropathic pain in patients with 
burns.74
The VAS or other numerical scoring systems were commonly 
used to report pruritus outcomes. However, other methods 
included itch episodes, breakthrough doses of antihistamines, 
and the itch severity scale. Difficulties were encountered due to 
these multiple reporting methods. Similar issues have been high-
lighted in other systematic reviews, often from pain management 
literature, highlighting the difficulties in standardizing and vali-
dating such outcome measures.75
This systematic review also limited the interventions being 
investigated to those drugs listed by NICE for the manage-
ment of neuropathic pain. Despite this wide inclusion criteria 
including multiple drugs and drugs classes, the literature search 
did not return any information on therapies such as other tricy-
clic antidepressants, including amitriptyline, or selective sero-
tonin reuptake inhibitors that have been used to manage pruritus 
in other conditions.76 77 Other therapies beyond pharmacolog-
ical management may be of benefit in pruritus, namely, psycho-
therapy such as cognitive behavioral therapy, transcutaneous 
electrical nerve stimulation, and acupuncture. These were not 
addressed in this review.9
CONCLUSIONS
Gabapentin appears effective in the management of pruritus 
associated with burn injury. Topical lidocaine may be a safe 
and effective option for managing pruritus in small surface area 
healed burns. Topical doxepin, although used to manage pruritus 
in eczema, does not appear to be effective in burn injuries.
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